Content

Targeting the Disease at Its Source Using Engineering Principles

Part of the BTEC Fall 2021 Seminar Series

Friday, Sept. 10, 2021
10:40–11:30 a.m.
Hosted on Zoom at go.ncsu.edu/btec_seminar.

A confluence of breakthroughs in genome sequencing, molecular biology, and patient information databases and registries provide the opportunity to make therapeutic leaps against genetic disease. BridgeBio works to create a bridge between promising genetic research and actual medicines with the people, platform, and processes needed to advance multiple individual therapies simultaneously. BridgeBio finds great science where the mechanism of a disease is well-understood and develops medicines that target those diseases at their source.

Speaker

Neil Kumar, Ph.D.
CEO and Founder, BridgeBio

About the presenter

Neil Kumar, Ph.D. has served as chief executive officer and a member of the BridgeBio board of directors since April 2015. Dr. Kumar has also served as the chief executive officer of its subsidiary, Eidos Therapeutics (Nasdaq: EIDX), a clinical stage biopharmaceutical company, and a member of the Eidos Therapeutics’ board of directors since March 2016. Prior to that, he served as the interim vice president of business development at MyoKardia, Inc. (Nasdaq: MYOK), a clinical stage biopharmaceutical company, from 2012 to 2014. Prior to that, Dr. Kumar served as a principal at Third Rock Ventures, a venture capital firm, from 2011 to 2014. Before joining Third Rock Ventures, he served as an associate principal at McKinsey & Company, a worldwide management consulting firm, from 2007 to 2011. Dr. Kumar has served as a member of the board of directors of LianBio since August 2020. He received his Bachelor of Science and Master of Science degrees in chemical engineering from Stanford University and received his Ph.D. in chemical engineering from the Massachusetts Institute of Technology.